NEW YORK (TheStreet) -- Pfizer (PFE) - Get Report ticked upward Wednesday after Goldman Sachs tagged a "buy" rating on the stock and set a $35 price target after the pharmaceutical giant dropped its $117 billion takeover bid for AstraZeneca (AZN) - Get Report.
The firm cited a "significant gap" between the current value and fair value of the share price.
"PFE has a significant cash position and [balance sheet] optionality and will likely use it to fill in gaps in growth through M&A," Goldman Sachs wrote in a research note. The firm added Pfizer's leadership "will do what it takes to unlock value, be it a break-up, M&A or whatever drives the most value."
Must Read: Warren Buffett's 25 Favorite Stocks
The stock was up 0.34% to $29.71 at 1:58 p.m.
PFE Price data by YCharts
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.